C-reactive protein and coronary events following percutaneous coronary angioplasty

American Journal of Medicine

Volumn 115, Issue 2, 2003, Pages 85-90

  De Winter, Robbert J ^a,b   Koch, Karel T ^a   Van Straalen, Jan P ^a   Heyde, Gerlind ^a   Bax, Matthijs ^a   Schotborgh, Carl E ^a   Mulder, Karla J ^a   Sanders, Gerard T ^a   Fischer, Johan ^a   Tijssen, Jan G P ^a   Piek, Jan J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REVASCULARIZATION; STABLE ANGINA PECTORIS; AGE DISTRIBUTION; BLOOD; COMORBIDITY; DIABETES MELLITUS; HYPERTENSION; INCIDENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; REOPERATION; RISK FACTOR; SEX RATIO; SMOKING; STATISTICS; SURVIVAL RATE; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGE DISTRIBUTION; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NETHERLANDS; PROSPECTIVE STUDIES; REOPERATION; RISK FACTORS; SEX DISTRIBUTION; SMOKING; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

EID: 0041736325     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00238-9     Document Type: Article

References (36)

1. Brakenhoff J.P.J., de Groot E.R., Evers R.F., Pannekoek H., Aarden L.A. Molecular cloning and expression of hybridoma growth factor in Escherichia coli. J Immunol. 139:1987;4116-4121.
2. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood. 86:1995;1243-1254.
3. Haverkate F., Thompson S.G., Pyke S.D.M., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 349:1997;462-466.
4. Kuller L.H., Tracy R.P., Shaten J., Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 144:1996;537-547.
5. Tracy R.P., Lemaitre R.N., Psaty B.M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 17:1997;1121-1127.
6. Anderson J.L., Muhlestein J.B., Horne B.D., et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation. 102:2000;1227-1232.
7. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 331:1994;417-424.
8. De Winter R.J., Bholasingh R., Lijmer J.G., et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc Res. 42:1999;240-245.
9. Rebuzzi A.G., Quaranta G., Liuzzo G., et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol. 82:1998;715-719.
10. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 99:1999;855-860.
11. Ferreiros E.R., Boissonnet C.P., Pizarro R., et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 100:1999;1958-1963.
12. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 343:2000;1139-1147.
13. Pietila K., Harmoinen A., Teppo A.M. Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant tissue type plasminogen activator. Ann Med. 23:1991;529-535.
14. Pietila K., Harmoinen A., Hermens W., et al. Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur Heart J. 14:1993;915-919.
15. Zhu J., Quyyumi A.A., Norman J.E., et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol. 85:2000;140-146.
16. Zhu J., Quyyumi A.A., Norman J.E., Csako G., Epstein S.E. Cytomegalovirus in the pathogenesis of atherosclerosis the role of inflammation as reflected by elevated C-reactive protein levels . J Am Coll Cardiol. 34:1999;1738-1743.
17. Roivainen M., Viik-Kajander M., Palosuo T., et al. Infections, inflammation, and the risk of coronary heart disease. Circulation. 101:2000;252-257.
18. Hack C.E., Wolbink G.J., Schalkwijk C., et al. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol Today. 18:1997;111-115.
19. Lagrand W.K., Visser C.A., Hermens W.T., et al. C-reactive protein as a cardiovascular risk factor more than an epiphenomenon? Circulation. 100:1999;96-102.
20. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2000;2165-2168.
21. Fichtlscherer S., Rosenberger G., Walter D.H., et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 102:2000;1000-1006.
22. Chew D.P., Bhatt D.L., Robbins M.A., et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 104:2001;992-997.
23. Buffon A., Liuzzo G., Biasucci L.M., et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 34:1999;1512-1521.
24. Gaspardone A., Crea F., Versaci F., et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol. 82:1998;515-518.
25. Versaci F., Gaspardone A., Tomai F., et al. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol. 85:2000;92-95.
26. Heeschen C., Hamm C.W., Bruemmer J., Simoons M.L. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. 35:2000;1535-1542.
27. Walter D.H., Fichtlscherer S., Britten M.B., et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol. 38:2001;2006-2012.
28. Zhou Y.F., Csako G., Grayston J.T., et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol. 84:1999;595-598.
29. Liuzzo G., Biasucci L.M., Rebuzzi A.G., et al. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation. 94:1996;2373-2380.
30. Liuzzo G., Biasucci L., Gallimore J.R., et al. Enhanced inflammatory response in patients with pre-infarction unstable angina. J Am Coll Cardiol. 34:1999;1696-1703.
31. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 100:1999;230-235.
32. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
33. Albert M.A., Staggers J., Chew P., Ridker P.M. The Pravastatin Inflammation CRP Evaluation (PRINCE) rationale and design . Am Heart J. 141:2001;893-898.
34. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study . JAMA. 286:2001;64-70.
35. Jialal I., Stein D., Balis D., et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 103:2001;1933-1935.
36. Serruys P.W., de Feyter P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention a randomized controlled trial. JAMA. 287:2002;3215-3222.